menu
    • menu
    [{"orgOrder":0,"company":"Semnur Pharmaceuticals","sponsor":"Denali Capital Acquisition Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Semnur to go Public via SPAC Merger with Denali Capital in $2.5 bln Deal","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2024","year":"2024","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Semnur Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp","highestDevelopmentStatusID":null,"companyTruncated":"Semnur Pharmaceuticals \/ Denali Capital Acquisition Corp"}]

    Find Clinical Drug Pipeline Developments & Deals by Semnur Pharmaceuticals

    Menu

    Semnur Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Semnur Pharmaceuticals

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed

                            Semnur Pharmaceuticals

                            U.S.A arrow
                            AAPS 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexamethasone Sodium Phosphate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Denali Capital Acquisition Corp

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Semnur to go Public via SPAC Merger with Denali Capital in $2.5 bln Deal

                            Details : Semnur’s lead program, Semdexa (dexamethasone sodium phosphate), is the first non-opioid novel injectable corticosteroid gel formulation for moderate to severe chronic radicular sciatica.

                            Brand Name : Semdexa

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 03, 2024

                            Lead Product(s) : Dexamethasone Sodium Phosphate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Denali Capital Acquisition Corp

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth